tiprankstipranks
Advertisement
Advertisement

SYRE Stock Latest News

Spyre Therapeutics price target raised to $130 from $100 at Wedbush
The FlySpyre Therapeutics price target raised to $130 from $100 at Wedbush
3d ago
SYRE
Spyre Therapeutics price target raised to $120 from $90 at Baird
PremiumThe Fly
Spyre Therapeutics price target raised to $120 from $90 at Baird
3d ago
SYRE
Spyre Therapeutics price target raised to $130 from $115 at Guggenheim
PremiumThe Fly
Spyre Therapeutics price target raised to $130 from $115 at Guggenheim
3d ago
SYRE
Spyre Therapeutics price target raised to $115 from $90 at Wells Fargo
PremiumThe Fly
Spyre Therapeutics price target raised to $115 from $90 at Wells Fargo
3d ago
SYRE
Spyre Therapeutics: Buy Rating Reiterated on Robust Pipeline, IBD Strategy and Strong Cash Runway; $112 Price Target Maintained
PremiumRatings
Spyre Therapeutics: Buy Rating Reiterated on Robust Pipeline, IBD Strategy and Strong Cash Runway; $112 Price Target Maintained
3d ago
SYRE
Spyre Therapeutics reports Q2 EPS (36c), consensus (75c)
PremiumThe FlySpyre Therapeutics reports Q2 EPS (36c), consensus (75c)
4d ago
SYRE
Spyre Therapeutics: Merck TL1A Readthrough Supports Multi-Disease Opportunity, Solid Cash Runway, and Unchanged $119 Buy Target
Premium
Ratings
Spyre Therapeutics: Merck TL1A Readthrough Supports Multi-Disease Opportunity, Solid Cash Runway, and Unchanged $119 Buy Target
4d ago
SYRE
Spyre Therapeutics downgraded to Peer Perform from Outperform at Wolfe Research
Premium
The Fly
Spyre Therapeutics downgraded to Peer Perform from Outperform at Wolfe Research
11d ago
SYRE
Spyre Therapeutics price target raised to $120 from $84 at Mizuho
PremiumThe Fly
Spyre Therapeutics price target raised to $120 from $84 at Mizuho
26d ago
SYRE
Spyre Therapeutics files automatic mixed securities shelf
PremiumThe Fly
Spyre Therapeutics files automatic mixed securities shelf
1M ago
SYRE
Spyre Therapeutics price target raised to $135 from $115 at Deutsche Bank
PremiumThe Fly
Spyre Therapeutics price target raised to $135 from $115 at Deutsche Bank
2M ago
SYRE
Tyler Van Buren Initiates Buy on Spyre Therapeutics, Citing Best‑in‑Class IBD Potential and $30B Rheumatology Opportunity
PremiumRatings
Tyler Van Buren Initiates Buy on Spyre Therapeutics, Citing Best‑in‑Class IBD Potential and $30B Rheumatology Opportunity
2M ago
SYRE
BTIG says others may be interested in Apogee Therapeutics
PremiumThe FlyBTIG says others may be interested in Apogee Therapeutics
2M ago
JNJ
NVS
Spyre Therapeutics Extends Long-Acting Antibody Program in IBD With New Long-Term Study
Premium
Company Announcements
Spyre Therapeutics Extends Long-Acting Antibody Program in IBD With New Long-Term Study
2M ago
SYRE
Spyre Therapeutics price target raised to $100 from $80 at Wedbush
Premium
The Fly
Spyre Therapeutics price target raised to $100 from $80 at Wedbush
2M ago
SYRE
Spyre Therapeutics: Buy Rating Reaffirmed as Positive SPY002 Ulcerative Colitis Data Supports $103 Price Target
PremiumRatings
Spyre Therapeutics: Buy Rating Reaffirmed as Positive SPY002 Ulcerative Colitis Data Supports $103 Price Target
2M ago
SYRE
Julian Harrison Reiterates Buy on Spyre Therapeutics, Lifts Price Target to $112 on Encouraging SPY002 Ulcerative Colitis Data and TL1A Platform Validation
PremiumRatings
Julian Harrison Reiterates Buy on Spyre Therapeutics, Lifts Price Target to $112 on Encouraging SPY002 Ulcerative Colitis Data and TL1A Platform Validation
2M ago
SYRE
Spyre Therapeutics price target raised to $112 from $98 at BTIG
PremiumThe Fly
Spyre Therapeutics price target raised to $112 from $98 at BTIG
2M ago
SYRE
Spyre Therapeutics Reports Strong Phase 2 SKYLINE Results
PremiumCompany Announcements
Spyre Therapeutics Reports Strong Phase 2 SKYLINE Results
2M ago
8K
SYRE
Spyre Therapeutics announces SKYLINE trial achieves primary endpoint
PremiumThe FlySpyre Therapeutics announces SKYLINE trial achieves primary endpoint
2M ago
SYRE
Spyre Therapeutics price target raised to $115 from $102 at Deutsche Bank
Premium
The Fly
Spyre Therapeutics price target raised to $115 from $102 at Deutsche Bank
2M ago
ABVX
SYRE
Spyre Therapeutics completes enrollment in SKYWAY basket trial of SPY072
Premium
The Fly
Spyre Therapeutics completes enrollment in SKYWAY basket trial of SPY072
2M ago
SYRE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >